Assessment of cytochrome P450 1A1 gene polymorphism and vitamin A serum level in psoriasis vulgaris

J Immunoassay Immunochem. 2023 May 4;44(3):269-282. doi: 10.1080/15321819.2023.2189471. Epub 2023 Mar 15.

Abstract

Psoriasis is characterized by cutaneous hyperproliferation, secondary to immune system dysregulation. Vitamin A regulates the immune response and sustains epithelial tissue hemostasis. The CYP1A1 gene, has many biological actions, including vitamin A metabolism. To evaluate CYP1A1 gene polymorphism and serum vitamin A level in patients with psoriasis vulgaris, a case-control study involving two groups was conducted: group 1 (45 patients with psoriasis vulgaris) served as the cased group and group 2 (45 healthy participants who were sex and age matched) acted as the control group. CYP1A1 (rs1048943) gene polymorphism and vitamin A serum level were assessed by TaqMan allelic discrimination (PCR) and ELISA, respectively. AG genotype was present only in cases (22.2%), while AA genotype was present in all controls (P=.001). Vitamin A levels were lower in cases than in controls (32.0 ± 7.41 vs. 46.2 ± 15.7 μg/ml, respectively) (P<.001). AG genotype was associated with a lower vitamin A level (P=.001). The detected genotype difference between psoriasis patients and controls, which was associated with a lower serum vitamin A level and was also lower in more severe cases, suggests a role of the CYP1A1 gene and vitamin A in disease pathogenesis and prognosis.

Keywords: CYP1A1; Psoriasis vulgaris; Vitamin A.

MeSH terms

  • Case-Control Studies
  • Cytochrome P-450 CYP1A1 / genetics
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Polymorphism, Genetic / genetics
  • Polymorphism, Single Nucleotide / genetics
  • Psoriasis* / genetics
  • Vitamin A*

Substances

  • Vitamin A
  • Cytochrome P-450 CYP1A1